Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757679 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL1804845 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL2517959 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4794837 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL1081182 | 0.90 | ALDH1A1 (0.53) | LPAR1LPAR3LPAR2 | |
| SCHEMBL303128 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4204833 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL8636551 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4879843 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4294185 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143751-A1 | INJECTABLE LONG-ACTING ANALGESIC PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-07-22 | — | — | WO | claimed |
| EP-0100910-B1 | LUNG SURFACTANT | A. Nattermann & Cie. GmbH (DE) | 1988-11-02 | — | — | EP | claimed |
| US-20220185918-A1 | AMPHIPHILIC COMPOUND, AND MEDICAL RESIN COMPOSITION AND PHARMACEUTICAL ADDITIVE USING THE SAME | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-16 | — | — | US | disclosed |
| WO-2022050369-A1 | LIPOSOME PREPARATION CONTAINING ANTIBACTERIAL DRUG | 国立大学法人大阪大学 | 2022-03-10 | — | — | WO | disclosed |
| EP-3950735-A1 | AMPHIPHILIC COMPOUND, AND RESIN COMPOSITION FOR MEDICAL USE AND DRUG ADDITIVE EACH USING SAME | Nippon Shokubai Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020203998-A1 | AMPHIPHILIC COMPOUND, AND RESIN COMPOSITION FOR MEDICAL USE AND DRUG ADDITIVE EACH USING SAME | 株式会社日本触媒 | 2020-10-08 | — | — | WO | disclosed |
| US-8367077-B2 | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof | PEVION BIOTECH, AG (CH) | 2013-02-05 | — | — | US | disclosed |
| CN-101815505-B | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof | PEVION BIOTECH AG | 2012-09-19 | — | — | CN | disclosed |
| EP-2182923-B1 | VIROSOMES COMPRISING HEMAGGLUTININ DERIVED FROM AN INFLUENZA VIRUS PRODUCED IN A CELL LINE, COMPOSITIONS, METHODS OF MANUFACTURING, USE THEREOF | PEVION BIOTECH AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20110045057-A1 | Virosomes Comprising Hemagglutinin Derived from an Influenza Virus Produced in a Cell Line, Compositions, Methods of Manufacturing, Use Thereof | PEVION BIOTECH, AG (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101815505-A | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof | PEVION BIOTECH AG | 2010-08-25 | — | — | CN | disclosed |
| EP-2014279-A1 | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof | Pevion Biotech AG (CH) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185918-A1 | AMPHIPHILIC COMPOUND, AND MEDICAL RESIN COMPOSITION AND PHARMACEUTICAL ADDITIVE USING THE SAME | LIPA, ABHD16A, ABCB11 | LPAR1 506/4885LPAR3 1130/4885LPAR2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.